Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

Hdl Handle:
http://hdl.handle.net/10144/619256
Title:
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study
Authors:
Schnippel, K; Ndjeka, N; Maartens, G; Meintjes, G; Master, I; Ismail, N; Hughes, J; Ferreira, H; Padanilam, X; Romero, R; Te Riele, J; Conradie, F
Journal:
Lancet Respiratory Medicine
Abstract:
Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 2015, especially among patients with extensively drug resistant tuberculosis for whom no other effective treatment options were available. We aimed to compare mortality in patients on standard regimens with that of patients on regimens including bedaquiline.
Publisher:
Elsevier
Issue Date:
9-Jul-2018
URI:
http://hdl.handle.net/10144/619256
DOI:
10.1016/S2213-2600(18)30235-2
PubMed ID:
30001994
Submitted date:
2018-07-17
Language:
en
ISSN:
2213-2619
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorSchnippel, Ken
dc.contributor.authorNdjeka, Nen
dc.contributor.authorMaartens, Gen
dc.contributor.authorMeintjes, Gen
dc.contributor.authorMaster, Ien
dc.contributor.authorIsmail, Nen
dc.contributor.authorHughes, Jen
dc.contributor.authorFerreira, Hen
dc.contributor.authorPadanilam, Xen
dc.contributor.authorRomero, Ren
dc.contributor.authorTe Riele, Jen
dc.contributor.authorConradie, Fen
dc.date.accessioned2018-08-08T16:25:42Z-
dc.date.available2018-08-08T16:25:42Z-
dc.date.issued2018-07-09-
dc.date.submitted2018-07-17-
dc.identifier.citationEffect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. 2018 Lancet Respir Meden
dc.identifier.issn2213-2619-
dc.identifier.pmid30001994-
dc.identifier.doi10.1016/S2213-2600(18)30235-2-
dc.identifier.urihttp://hdl.handle.net/10144/619256-
dc.description.abstractAddition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 2015, especially among patients with extensively drug resistant tuberculosis for whom no other effective treatment options were available. We aimed to compare mortality in patients on standard regimens with that of patients on regimens including bedaquiline.en
dc.language.isoenen
dc.publisherElsevieren
dc.rightsArchived with thanks to Lancet Respiratory Medicineen
dc.titleEffect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort studyen
dc.identifier.journalLancet Respiratory Medicineen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.